Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Increases By 47.1%

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a significant increase in short interest in December. As of December 31st, there was short interest totaling 212,833 shares, an increase of 47.1% from the December 15th total of 144,691 shares. Currently, 2.0% of the company’s stock are short sold. Based on an average daily volume of 345,914 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 345,914 shares, the short-interest ratio is presently 0.6 days. Currently, 2.0% of the company’s stock are short sold.

Azitra Stock Performance

Shares of AZTR stock traded down $0.02 during mid-day trading on Friday, reaching $0.33. 4,260,324 shares of the stock traded hands, compared to its average volume of 879,012. The stock’s fifty day simple moving average is $0.33 and its two-hundred day simple moving average is $0.75. Azitra has a 1-year low of $0.26 and a 1-year high of $3.92.

Azitra (NYSEAMERICAN:AZTR) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.12. Equities research analysts forecast that Azitra will post -2.78 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Maxim Group reduced their price target on Azitra from $13.32 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 24th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Azitra currently has an average rating of “Buy” and a consensus target price of $4.00.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.